Bridging the knowledge gap: cytomegalovirus (CMV) awareness in the kidney transplant community

Afolarin A Otunla¹, Katie Gilchrist², Ailey McLeod², Cecilia Vindrola², Reza Motallebzadeh^{1,3,4}

¹Research Department of Surgical Biotechnology, University College London, London, NW3 2PP, UK , ²Department of Targeted Intervention, University College London, London, W1W 7TY, UK , ³Institute of Immunity and Transplantation, University College London, London, London, NW3 2PP, UK , ⁴Department of Nephrology & Transplantation, Royal Free Hospital, London, NW3 2QG, UK

Background

- Cytomegalovirus (CMV) is one of the most common opportunistic infectious complications of solid organ transplantation, with a 1- year incidence of up to 31.3% in donor positive, recipient negative (D+/R-) populations and 3.2% in donor negative, recipient negative (D-/R-) populations.
- The clinical spectrum ranges from asymptomatic viraemia, to non-specific symptoms such as fever, night sweats, fatigue
 and myalgia, and ultimately to tissue-invasive disease including retinitis, colitis and pneumonitis.
- Post-transplant infection with CMV is associated not only with the aforementioned sequalae, but can also significantly

increase the risk of graft rejection, premature graft failure and mortality.

 Despite its ubiquity and potentially devastating consequences, there is currently no data exploring the kidney transplant patient experience of CMV.

Methods

- We performed semi-structured interviews with 50 adult recipients who had undergone kidney transplantation within the last two years in our centre.
- Participants were divided into two groups: those who had experienced CMV (CMV group, n=25) and those who had not (non-CMV group, n=25).
- Transcripts were analysed using a combination of qualitative and quantitative techniques to generate data across three themes: awareness of CMV and its management, effect of CMV infection on quality of life and efficacy of current treatment.






Figure 1. Word cloud of terms used by participants to describe their knowledge and awareness of CMV. The figure was generated by analysing interview transcripts using Pythons 'WordCloud' library (version 1.8.1) on October 29th 2024. The size of each word is proportional to its frequency, ranging from n=1 ("vague") to n=18 ("nothing").

	CMV	Non-CMV	
Interview Question	(n = 25)	(n = 25)	P-Values

Structured interviews Lin-depth interviews Servi- structured interviews	Number of participants who worried about the impact of CMV on their overall health (%)	16 (64)	15 (60)	1
	Number of participants who worried about the impact of CMV on their kidney transplant (%)	14 (56)	12 (48)	0.79
	Number of participants aware of CMV at the time of interview (%)	22 (88)	8 (32)	<0.001
	How worried were participants about CMV on a 10-point Likert scale; median (Q1-Q3)	2.5 (1-4.375)	0 (0-1)	<0.001
ving information on CMV	Number of participants who thought they would recognise the symptoms of CMV (%)	6 (24)	1 (4)	0.1
mptoms in themselves.	Number of patients who thought more should be done to educate transplant recipients about CMV(%)	19 (76)	22 (88)	0.7
rry about CMV as 2.5 out of	Number of patients who were aware of the difference between prophylactic and pre-emptive anti-CMV management (%)	6(24)	-	
	Number of patients who thought that			

more should be done to explain the

difference between prophylactic and pre-

emptive approaches

Results

Poor awareness of CMV:

- 60% did not remember receiving information on CMV prior to transplant.
- 23% would recognise the symptoms in themselves.
- Participants rated overall worry about CMV as 2.5 out of 10 on 10 point Likert scale.

Limited Impact of CMV

 85% did not recall experiencing any CMV related symptoms

Effective management of CMV

Table 1. Summary of responses by the CMV cohort to key interview questions on the impact of CMV and the efficacy of its treatment.

18 (72)

Conclusions

 Participants rated the efficacy of CMV treatment as 9.5/10.

Need for further education on CMV

- 82% of participants thought that more should be done to inform kidney transplant recipients about CMV.
- Low awareness: There is a significant gap in CMV awareness among kidney transplant recipients.
- Desire for further education: Kidney transplant recipients expressed a strong desire for improved CMV education.
- Clinical implications: Enhancing patient education on CMV could improve post-transplant outcomes by empowering recipients to recognize symptoms and seek timely care.

Dr Afolarin Otunla a.otunla@nhs.net